Loading...
XSHE000627
Market cap2.53bUSD
Jan 16, Last price  
3.85CNY
1D
2.39%
1Q
17.38%
Jan 2017
-49.67%
Name

Hubei Biocause Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHE:000627 chart
P/E
—
P/S
0.37
EPS
—
Div Yield, %
2.93%
Shrs. gr., 5y
0.41%
Rev. gr., 5y
9.93%
Revenues
49.70b
+0.17%
463,045,597518,724,940560,753,742835,759,421909,282,121964,602,6191,261,158,9691,133,763,402779,736,170967,950,657806,442,682541,107,13616,995,545,66153,405,580,05430,950,844,34950,192,084,32243,575,986,58049,583,190,77749,615,695,08049,698,873,747
Net income
-652m
L
5,090,4107,099,45848,366,26089,708,084055,761,62828,322,248011,824,926083,822,760247,266,6651,778,718,9291,326,164,1781,326,520,0922,918,553,0691,117,905,848880,217,955510,619,669-651,758,543
CFO
9.53b
+26.71%
56,066,24448,656,281128,188,960118,556,60500224,584,78366,946,08093,791,251130,534,730000431,578,20914,981,339,56928,599,558,51621,421,088,4204,172,608,4017,524,197,2739,534,242,316
Dividend
May 30, 20230.11 CNY/sh
Earnings
May 23, 2025

Profile

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. The company also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, it is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. The company exports its products to the United States, the European Union, and internationally. Hubei Biocause Pharmaceutical Co., Ltd. is based in Jingmen, China.
URL
http://www.biocause.com
IPO date
Nov 12, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
49,698,874
0.17%
49,615,695
0.07%
Cost of revenue
10,303,333
9,240,557
Unusual Expense (Income)
NOPBT
39,395,541
40,375,138
NOPBT Margin
79.27%
81.38%
Operating Taxes
(586,505)
Tax Rate
NOPAT
39,982,045
40,375,138
Net income
(651,759)
-227.64%
510,620
-41.99%
Dividends
(543,469)
(24,703)
Dividend yield
3.82%
0.16%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
18,248,100
21,189,583
Long-term debt
7,242,334
6,967,472
Deferred revenue
49,720
241,834
Other long-term liabilities
235,241,382
220,542,642
Net debt
(138,358,740)
(129,977,966)
Cash flow
Cash from operating activities
9,534,242
7,524,197
CAPEX
(67,529)
Cash from investing activities
(3,642,412)
Cash from financing activities
(4,096,246)
11,077,822
FCF
52,878,645
40,934,337
Balance
Cash
29,952,030
28,391,826
Long term investments
133,897,144
129,743,195
Excess cash
161,364,230
155,654,236
Stockholders' equity
22,638,162
24,640,131
Invested Capital
271,705,570
258,729,622
ROIC
15.08%
16.44%
ROCE
13.32%
14.18%
EV
Common stock shares outstanding
5,013,527
4,940,629
Price
2.84
-10.13%
3.16
-4.53%
Market cap
14,238,417
-8.80%
15,612,388
-4.53%
EV
(111,076,625)
(100,088,772)
EBITDA
39,547,914
40,522,408
EV/EBITDA
Interest
31,200,622
Interest/NOPBT
77.28%